CD63 and breast carcinoma: In breast cancer, one study identified a subset of Cluster of Differentiation 63 (CD63+) CAFs in ER-positive breast cancer that are enriched in tumors resistant to CDK4/6 inhibitors (CDK4/6i) [164].